Results 241 to 250 of about 284,370 (314)

Complete and durable response to trastuzumab deruxtecan in HER2-amplified invasive vulvar adenocarcinoma: A case report. [PDF]

Gynecol Oncol Rep
Barr AP, Nakamura N, Nguyen NT.
europepmc   +1 more source

Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background The management of intermediate‐risk early prostate cancer (PCa) is challenging due to the difficulty in distinguishing indolent from aggressive tumors. This study explores the association between genomic alterations and the tumor and its microenvironment (TME) and implications for disease progression. Methods We performed multi‐omic
William Lautert‐Dutra, Camila M. Melo, Luiz P. Chaves, Francisco C. Souza, Vida Talebian, Cheryl Crozier, Mary Anne Quintayo, Linda Liao, Dan Dion, Fabiano P. Saggioro, Felipe S. Avante, Rodolfo B. dos Reis, Jeremy A. Squire, Jane Bayani   +13 more
wiley   +1 more source

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes. [PDF]

Clin Cancer Res
Conte B, Brasó-Maristany F, Pascual T, Hernando C, Vázquez S, Blanch S, Oliveira M, Virizuela JA, Muñoz M, Seguí E, Rodriguez-Hernandez A, Vidal Losada MJ, Galván P, Castillo O, Blasco P, Alva M, Chic N, Sanfeliu E, Cano-Crespo S, Salvador F, Villacampa G, Villanueva L, Ferrero-Cafiero JM, Vivancos A, Prat A, Ciruelos E.   +25 more
europepmc   +1 more source

Natural Products as Modulators of ABC Transporters in Breast Cancer

Phytotherapy Research, EarlyView.
ABSTRACT Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple‐negative breast cancer (TNBC), continues to hinder effective therapy.
Yoganishalini Sagadevan, Reyhaneh Farghadani, Ammu K. Radhakrishnan   +2 more
wiley   +1 more source

Clinical application and optimization strategies for antibody-drug conjugates in solid tumors. [PDF]

J Int Med Res
Qu J, Zhao X, Zhang L, Cai W, Shen M, Liu X, Wei X, Fei F.   +7 more
europepmc   +1 more source

2D van der Waals System Integrated with Targeting Radio‐Diagnostic and Imaging Functions

Small, EarlyView.
Layered double hydroxide (LDH) nanoplates were engineered for tumor‐targeted imaging and therapy. By exploiting folate receptor (FR) expression levels, the system achieves selective tumor accumulation and high‐resolution dual PET/fluorescence (PET/FL) imaging.
Sairan Eom, Jae Hun Ahn, Jung Yung Kim, Kyo Chul Lee, Yong Jin Lee, Sanoj Rejinold N, Jin‐Ho Choy   +6 more
wiley   +1 more source

Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates. [PDF]

World J Oncol
Zheng ZN, Ye XH, Shen XB, Li T, Guo J.
europepmc   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis. [PDF]

Breast Cancer Res Treat
Tam G, Waddell D, Freeman JQ, Chen N, Yang H.   +4 more
europepmc   +1 more source